Evidence map›Paper›PMID 40520866›Full record

ArticleAmerican journal of cancer research2025

Kang Ru enhances paclitaxel's efficacy against breast cancer progression.

Chun-Ming Chang, Chikondi Jassi, Wei-Wen Kuo, Yu-Jung Lin, Chih-Hao Chiu, Tsai-Ting Wu, Chia-Hua Kuo, Tsung-Jung Ho, Shinn-Zong Lin, Chih-Yang Huang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Chun-Ming ChangDepartment of General Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 970, Taiwan.
Chikondi JassiCardiovascular and Mitochondria Related Diseases Research Center, Hualien Tzu Chi Hospital Hualien 970, Taiwan.
Wei-Wen KuoDepartment of Biological Science and Technology, China Medical University Taichung 40676, Taiwan.
Yu-Jung LinCardiovascular and Mitochondria Related Diseases Research Center, Hualien Tzu Chi Hospital Hualien 970, Taiwan.
Chih-Hao ChiuCardiovascular and Mitochondria Related Diseases Research Center, Hualien Tzu Chi Hospital Hualien 970, Taiwan.
Tsai-Ting WuCardiovascular and Mitochondria Related Diseases Research Center, Hualien Tzu Chi Hospital Hualien 970, Taiwan.
Chia-Hua KuoLaboratory of Exercise Biochemistry, University of Taipei Taipei 10048, Taiwan.
Tsung-Jung HoDepartment of Chinese Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 970, Taiwan.
Shinn-Zong LinBioinnovation Center, Buddhist Tzu Chi Medical Foundation Hualien 970, Taiwan.
Chih-Yang HuangCardiovascular and Mitochondria Related Diseases Research Center, Hualien Tzu Chi Hospital Hualien 970, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer and its associated drug resistance present significant clinical challenges. From a translational medicine perspective, Traditional Chinese Herbal Medicine (TCHM) offers promising integrative approach to bridge the experimental findings with clinical application, enhancing cancer treatment outcomes and mitigate drug resistance. In this study, we evaluated a TCM herbal formulation, Kang Ru (KR), comprising

Indexed as

Breast cancerdrug efficacyherbal formulationKang Rupaclitaxel

Identifiers

PMID40520866
PMCPMC12163460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.